T5O.DE
Price:
$0.32
Market Cap:
$164.40K
CytoTools AG, a biotechnology company, develops a pipeline of disease modifying therapies. The company's therapies include proprietary small molecules and biologics to provide treatment options in dermatology, cardiology and angiology, urology, and oncology. Its lead clinical product is DermaPro that has completed Phase III clinical trials for the treatment of diabetic foot ulcers in India; is in Phase III clinical trials for diabetic foot ulcer treatment in Europe; and is in Phase II/III clinical studies for the treatment of venous leg ulcers in Germany, as well as is used as an anti-infective. The company also develops Utisept, an urological medical device for flushing the bladder in urina...[Read more]
Industry
Biotechnology
IPO Date
2006-12-18
Stock Exchange
XETRA
Ticker
T5O.DE
According to CytoTools AG’s latest financial reports and current stock price. The company's current PE Ratio is -0.25. This represents a change of -95.51% compared to the average of -5.53 of the last 4 quarters.
The mean historical PE Ratio of CytoTools AG over the last ten years is -24.94. The current -0.25 PE Ratio has changed -0.54% with respect to the historical average. Over the past ten years (40 quarters), T5O.DE's PE Ratio was at its highest in in the June 2009 quarter at 0. The PE Ratio was at its lowest in in the June 2014 quarter at -124.05.
Average
-24.94
Median
-16.64
Minimum
-106.40
Maximum
-0.02
Discovering the peaks and valleys of CytoTools AG PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 131.23%
Maximum Annual PE Ratio = -0.02
Minimum Annual Increase = -99.76%
Minimum Annual PE Ratio = -106.40
| Year | PE Ratio | Change |
|---|---|---|
| 2023 | -0.02 | -99.76% |
| 2022 | -6.88 | 53.52% |
| 2021 | -4.48 | -86.88% |
| 2020 | -34.17 | 13.98% |
| 2019 | -29.98 | 123.57% |
| 2018 | -13.41 | -35.47% |
| 2017 | -20.78 | 18.22% |
| 2016 | -17.58 | 11.93% |
| 2015 | -15.70 | -85.24% |
| 2014 | -106.40 | 131.23% |
The current PE Ratio of CytoTools AG (T5O.DE) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-3.79
5-year avg
-15.11
10-year avg
-24.94
CytoTools AG’s PE Ratio is greater than Biofrontera AG (-0.46), greater than Paion AG (-4.44), greater than FamiCord AG (-11.62), greater than Viscom AG (-6.43), greater than Syzygy AG (-1.46),
| Company | PE Ratio | Market cap |
|---|---|---|
| -0.46 | $20.67M | |
| -4.44 | $2.71M | |
| -11.62 | $118.54M | |
| -6.43 | $36.07M | |
| -1.46 | $21.60M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like CytoTools AG using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like CytoTools AG or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is CytoTools AG's PE Ratio?
How is the PE Ratio calculated for CytoTools AG (T5O.DE)?
What is the highest PE Ratio for CytoTools AG (T5O.DE)?
What is the 3-year average PE Ratio for CytoTools AG (T5O.DE)?
What is the 5-year average PE Ratio for CytoTools AG (T5O.DE)?
How does the current PE Ratio for CytoTools AG (T5O.DE) compare to its historical average?